Cargando…

Whole-Body MRI vs. PET/CT for the Detection of Bone Metastases in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis

Purpose: A recent meta-analysis in patients with non-small cell lung cancer showed no difference between whole-body magnetic resonance imaging (WBMRI) and positron emission tomography/computed tomography (PET/CT), but no such study is available for prostate cancer (PCa). This study aimed to compare...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhan, Yuefu, Zhang, Guangming, Li, Mingliang, Zhou, Xiaobo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130579/ https://www.ncbi.nlm.nih.gov/pubmed/34017680 http://dx.doi.org/10.3389/fonc.2021.633833

Ejemplares similares

Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography
por: Oprea-Lager, Daniela E., et al.
Publicado: (2021)

The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer
por: Ottosson, Fredrik, et al.
Publicado: (2020)

Whole-body MRI: detecting bone metastases from prostate cancer
por: Nakanishi, Katsuyuki, et al.
Publicado: (2021)

Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients
por: Bruckmann, Nils Martin, et al.
Publicado: (2021)

Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies
por: Liu, Fanxiao, et al.
Publicado: (2021)

Whole body MRI and PET/CT in haematological malignancies
por: Lin, Chieh, et al.
Publicado: (2007)

Diagnostic performance of integrated whole-body (18)F-FDG PET/MRI for detecting bone marrow involvement in indolent lymphoma: Comparison with (18)F-FDG PET or MRI alone
por: Chen, Xuetao, et al.
Publicado: (2023)

A Pilot Study of (18)F-DCFPyL PET/CT or PET/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions
por: Liu, Yachao, et al.
Publicado: (2021)

Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis
por: Zhang, Cici, et al.
Publicado: (2023)

Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
por: Maccioni, Francesca, et al.
Publicado: (2023)

Cost-effectiveness analysis of MRI, CE-CT and 18F-FDG PET/CT for detecting colorectal liver metastases eligible for hepatic resection
por: Schnitzer, Moritz L., et al.
Publicado: (2023)

Microstructure Characterization of Bone Metastases from Prostate Cancer with Diffusion MRI: Preliminary Findings
por: Bailey, Colleen, et al.
Publicado: (2018)

Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT
por: Ingenerf, Maria, et al.
Publicado: (2023)

The Value of (18)F-FDG PET/CT and Abdominal PET/MRI as a One-Stop Protocol in Patients With Potentially Resectable Colorectal Liver Metastases
por: Zhou, Nina, et al.
Publicado: (2021)

Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study
por: Hinzpeter, Ricarda, et al.
Publicado: (2021)

Choline PET/CT in recurrent prostate cancer
por: Detti, Beatrice, et al.
Publicado: (2023)

Case Report: (18)F-PSMA PET/CT May Improve the Clinical Management of Penile Metastases From Prostate Cancer
por: Fan, Junjie, et al.
Publicado: (2021)

Detection and Segmentation of Pelvic Bones Metastases in MRI Images for Patients With Prostate Cancer Based on Deep Learning
por: Liu, Xiang, et al.
Publicado: (2021)

Predictors of patient preference for either whole body magnetic resonance imaging (WB‐MRI) or CT/ PET‐CT for staging colorectal or lung cancer
por: Miles, Anne, et al.
Publicado: (2020)

Trimodality PET/CT/MRI and Radiotherapy: A Mini-Review
por: Decazes, Pierre, et al.
Publicado: (2021)

Does whole-body bone SPECT/CT provide additional diagnostic information over [18F]-FCH PET/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?
por: de Leiris, Nicolas, et al.
Publicado: (2020)

(18)F-PSMA-1007 PET/CT Performance on Risk Stratification Discrimination and Distant Metastases Prediction in Newly Diagnosed Prostate Cancer
por: Wang, Zhuonan, et al.
Publicado: (2021)

PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases
por: Sadetski, Igor, et al.
Publicado: (2021)

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer
por: Ming, Yue, et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

MRI and amino acid PET detection of whole-brain tumor burden
por: Chen, Peng, et al.
Publicado: (2023)

Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

Development of a Hybrid-Imaging-Based Prognostic Index for Metastasized-Melanoma Patients in Whole-Body 18F-FDG PET/CT and PET/MRI Data
por: Küstner, Thomas, et al.
Publicado: (2022)

Intraindividual Comparison Between [(18)F] PSMA-1007 PET/CT and Multiparametric MRI for Radiotherapy Planning in Primary Prostate Cancer Patients
por: Marinescu, Ioana M., et al.
Publicado: (2022)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Advanced Imaging of Biochemical Recurrent Prostate Cancer With PET, MRI, and Radiomics
por: Shaikh, Faiq, et al.
Publicado: (2020)

Detection of Recurrent Prostate Cancer With (18)F-Fluciclovine PET/MRI
por: Selnæs, Kirsten Margrete, et al.
Publicado: (2020)

Value of (18)F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With (18)F-FDG PET/CT, MRI, and Contrast-Enhanced CT
por: Wang, Fei, et al.
Publicado: (2022)

Tumor- and Osteoblast-Derived Periostin in Prostate Cancer bone Metastases
por: Sun, Chuan-Yu, et al.
Publicado: (2022)

Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases
por: Donners, Ricardo, et al.
Publicado: (2023)

11C-choline PET/CT and whole-body MRI including diffusion-weighted imaging for patients with recurrent prostate cancer
por: Wieder, Hinrich, et al.
Publicado: (2017)

Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis
por: Bin, Xu, et al.
Publicado: (2020)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer
por: Huang, Shi-ming, et al.
Publicado: (2018)

Synthetic CT generation for MRI-guided adaptive radiotherapy in prostate cancer
por: Hsu, Shu-Hui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o2a84nvqbo47vfkh9m621m1k0c